IDP 023
Alternative Names: IDP-023Latest Information Update: 08 Aug 2024
At a glance
- Originator Indapta Therapeutics
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HLA antigen modulators; Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma
- Preclinical Multiple sclerosis; Solid tumours
Most Recent Events
- 06 Aug 2024 Preclinical trials in Multiple sclerosis in USA (Parenteral), prior to August 2024
- 06 Aug 2024 US FDA approves IND application for IDP 023 in Multiple sclerosis
- 06 Aug 2024 Indapta Therapeutics in collaboration with Stanford University and the University of California plans a phase I trial for Multiple sclerosis (Combination therapy) in 2024